Delavirdine: clinical pharmacokinetics and drug interactions

Clinical Pharmacokinetics
J Q TranB M Kerr

Abstract

Delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is a potent and specific inhibitor of HIV-1 reverse transcriptase. The approved therapeutic regimen for delavirdine is 400mg 3 times daily in combination with appropriate antiretroviral agents; however, a dose of 600mg twice daily appears to provide similar systemic exposure. The steady-state pharmacokinetics of delavirdine are not appreciably affected by food. Delavirdine undergoes extensive metabolism by cytochrome P450 (CYP) with little urinary excretion of unchanged drug. Metabolic drug interactions between delavirdine and nucleoside reverse transcriptase inhibitors are unlikely as their metabolic pathways differ; delavirdine has no effect on the pharmacokinetics of zidovudine. Concomitant use of CYP inducers, such as rifampicin (rifampin), rifabutin, phenytoin, phenobarbital or carbamazepine, should be avoided since delavirdine plasma concentrations are significantly lowered. Reduction in gastric acidity (pH > 3) decreases the extent of delavirdine absorption, so administration of antacids and the buffered formulations of didanosine should be separated from that of delavirdine by at least 1 hour. Delavirdine, unlike other currently available NNRTI agent...Continue Reading

References

Jan 1, 1996·Advances in Experimental Medicine and Biology·W W Freimuth
Apr 1, 1996·Clinical Pharmacokinetics·E P AcostaC V Fletcher
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·D ZakulaR C Goldman
May 1, 1997·Clinical Pharmacology and Therapeutics·C L ChengP L Stetson
May 1, 1997·Clinical Pharmacology and Therapeutics·M T BorinW W Freimuth
Apr 16, 1998·Clinical Pharmacokinetics·S Vella, M Floridia
Apr 29, 1998·Journal of Clinical Pharmacology·L L von MoltkeR I Shader
Jul 2, 1998·Journal of Pharmaceutical Sciences·C J DeckerP R Chaturvedi
Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Jul 17, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J J FerryD H Batts
Oct 1, 1998·Antiviral Research·C Scholtissek, R G Webster
Oct 17, 1998·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·A L Tseng
Nov 13, 1998·Clinical Pharmacokinetics·A HsuR J Bertz
Jan 8, 1999·Drugs·J C Adkins, S Noble
Jul 3, 1999·Pharmacotherapy·E P AcostaC V Fletcher
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
May 9, 2000·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Jun 24, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·A L GiffordS A Bozzette
Mar 17, 2001·The Journal of Antimicrobial Chemotherapy·F BarchiesiM A Viviani

❮ Previous
Next ❯

Citations

Feb 7, 2002·Pharmacoepidemiology and Drug Safety
May 9, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ching-Ling ChengOliver Yoa-Pu Hu
Jan 22, 2003·British Journal of Clinical Pharmacology·Ulrik S JustesenCourt Pedersen
Sep 1, 2004·Pharmacogenomics·Annalise M MartinSimon Mallal
Feb 27, 2003·Clinical Pharmacokinetics·Monique M R de MaatJos H Beijnen
May 31, 2007·Clinical Drug Investigation·Gene D MorseRichard C Reichman
Feb 15, 2012·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Alicia R DesiletsKaelen C Dunican
May 16, 2009·Expert Opinion on Drug Metabolism & Toxicology·Laura MacDonaldBrian C Foster
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Aug 2, 2003·Biological Psychiatry·Dean G CruessJohn M Petitto
Jun 4, 2008·Psychosomatic Medicine·Martin J Repetto, John M Petitto
Mar 6, 2003·Journal of Clinical Pharmacology·Mark J SheltonGene D Morse
Sep 24, 2004·Therapeutic Drug Monitoring·Christopher S AlexanderP Richard Harrigan
Dec 5, 2008·Alimentary Pharmacology & Therapeutics·E LahnerG Delle Fave
Jun 28, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·John G GerberUNKNOWN AIDS Clinical Trials Group A5108 Team
Jul 23, 2019·Expert Opinion on Drug Delivery·Yuqing GongSantosh Kumar
Aug 19, 2014·World Journal of Gastroenterology : WJG·Edith LahnerMarco Centanni
Jan 24, 2002·Therapeutic Drug Monitoring·Petrie M Rainey
Aug 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Gang LuoLiang-Shang Gan
Nov 17, 2010·Journal of Molecular Modeling·Jayakanthan MannuPremendu P Mathur
Mar 19, 2019·Organic & Biomolecular Chemistry·Yuxiang ZhouPeijun Liu
Nov 18, 2020·Current Opinion in Pharmacology·Murugesan VanangamudiVigneshwaran Namasivayam
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·P AmarilesM J Faus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved